The treatment of ovarian cancer with paclitaxels / 肿瘤研究与临床

ABSTRACT

Objective To study the effect and toxicities of paclitaxel combined with platinum(TP) and paclitaxel(Chinese) combined with platinum (PTP) in the treatment of epithelial ovarian cancer, and to compare with the combination of cyclophosphamide,adriamycin and platinum(CAP). Methods A retrospective analysis in the treatment of ovarian cancer with paclitaxel and CAP from 2000 to 2004 was done. Including 28 cases in TP, 22 cases in PTP and 18 cases in CAP group. Result The response rate (RR) in TP,PTP and CAP was expectively 53.6 %, 54.5 % and 44.4 %. In frist line chemotherapy, the RR in TP, PTP and CAP was expectively 83.3 %, 62.5 % and 50.0 %; and in second line chemotherapy, the RR in TP, PTP and CAP was expectively 31.2 %, 33.3 % and 25.0 %. Compared the RR of three groups, TP and PTP group were higher than CAP group (P